http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101695237-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2013-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101695237-B1 |
| titleOfInvention | Composition for relief and treatment of liver injury comprising Bortezomib as a active ingredient |
| abstract | The present invention relates to a composition for relieving and treating hepatotoxicity which contains bortezomib (PS-341) as an active ingredient. More particularly, the present invention relates to a composition for relieving and treating hepatotoxicity comprising bortezomib AST and ALT values indicating blood toxicity indicating hepatotoxicity were significantly decreased and analysis of liver tissues through dyeing revealed that hepatotoxicity-induced liver tissue damage was reduced. As a result, it was confirmed that the bortezomib of the present invention was a hepatotoxic emollient And as a therapeutic agent. |
| priorityDate | 2013-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.